Diabetes

DiabetesWise Pro founder highlights the 3 most beneficial website features to help clinicians compare all the available CGMs, delivery systems, AIDs, and smart pens.

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

ENDO 2022: The large US analysis found persons with prediabetes had increased odds for heart attack of 25%, for PCI of 45%, and had nearly double the risk of having CABG.

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.

ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.

ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.

The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.